Scholar Rock Holding Corp(SRRK)高管表示,公司预计在美国市场,典型患者每年的净治疗费用将接近31万美元。这一预期数字揭示了该疗法的定价策略及其对患者经济负担的潜在影响。
Scholar Rock Holding Corp(SRRK)高管表示,公司预计在美国市场,典型患者每年的净治疗费用将接近31万美元。这一预期数字揭示了该疗法的定价策略及其对患者经济负担的潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.